{"pmid":32387547,"title":"Response to: RILI model and the Covid-19 pneumonia: the radiation oncologist point of view.","text":["Response to: RILI model and the Covid-19 pneumonia: the radiation oncologist point of view.","Radiother Oncol","Kirkby, Charles","Mackenzie, Marc","32387547"],"journal":"Radiother Oncol","authors":["Kirkby, Charles","Mackenzie, Marc"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32387547","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.radonc.2020.04.050","locations":["RILI"],"topics":["Prevention"],"weight":1,"_version_":1666428892584345600,"score":9.490897,"similar":[{"pmid":32389754,"title":"RILI model and the Covid-19 pneumonia: the radiation oncologist point of view.","text":["RILI model and the Covid-19 pneumonia: the radiation oncologist point of view.","Radiother Oncol","Lazzari, Grazia","Silvano, Giovanni","32389754"],"journal":"Radiother Oncol","authors":["Lazzari, Grazia","Silvano, Giovanni"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32389754","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.radonc.2020.04.027","topics":["Mechanism","Treatment"],"weight":1,"_version_":1666528579986391040,"score":158.93152},{"pmid":32295769,"pmcid":"PMC7199912","title":"Radiation therapy during the coronavirus disease 2019 (covid-19) pandemic in Italy: a view of the nation's young oncologists.","text":["Radiation therapy during the coronavirus disease 2019 (covid-19) pandemic in Italy: a view of the nation's young oncologists.","ESMO Open","Meattini, Icro","Franco, Pierfrancesco","Belgioia, Liliana","Boldrini, Luca","Botticella, Angela","De Santis, Maria Carmen","Marvaso, Giulia","Montesi, Giampaolo","Parisi, Silvana","Triggiani, Luca","Lambertini, Matteo","Livi, Lorenzo","32295769"],"journal":"ESMO Open","authors":["Meattini, Icro","Franco, Pierfrancesco","Belgioia, Liliana","Boldrini, Luca","Botticella, Angela","De Santis, Maria Carmen","Marvaso, Giulia","Montesi, Giampaolo","Parisi, Silvana","Triggiani, Luca","Lambertini, Matteo","Livi, Lorenzo"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32295769","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1136/esmoopen-2020-000779","keywords":["covid-19","clinical oncology","radiation therapy","recommendations","young oncologists"],"link_comment_for":"32229501","locations":["Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Treatment"],"weight":1,"_version_":1666138493198270464,"score":60.184677},{"pmid":32348049,"title":"[COVID-19 from the nephrologist's point of view].","text":["[COVID-19 from the nephrologist's point of view].","During the actual pandemic of COVID-19, it has become clear that the virus causing this devastating disease, SARS-CoV2, targets not only the lungs but also other organs. In this article, we discuss the known or suspected interactions between the virus and the kidneys, as well as their clinical presentations. We also discuss how the pandemic has altered the activities of nephrologists and the logistics of a Swiss dialysis center.","Rev Med Suisse","Kissling, Sebastien","Pruijm, Menno","32348049"],"abstract":["During the actual pandemic of COVID-19, it has become clear that the virus causing this devastating disease, SARS-CoV2, targets not only the lungs but also other organs. In this article, we discuss the known or suspected interactions between the virus and the kidneys, as well as their clinical presentations. We also discuss how the pandemic has altered the activities of nephrologists and the logistics of a Swiss dialysis center."],"journal":"Rev Med Suisse","authors":["Kissling, Sebastien","Pruijm, Menno"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32348049","source":"PubMed","week":"202018|Apr 27 - May 03","locations":["Swiss"],"countries":["Switzerland"],"countries_codes":["CHE|Switzerland"],"topics":["Prevention"],"weight":1,"_version_":1666138494961975297,"score":53.61658},{"pmid":32342881,"pmcid":"PMC7175025","title":"COVID-19 and gynecological cancers: A Moroccan point-of-view.","text":["COVID-19 and gynecological cancers: A Moroccan point-of-view.","Radiother Oncol","Ismaili, Nabil","32342881"],"journal":"Radiother Oncol","authors":["Ismaili, Nabil"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32342881","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.radonc.2020.04.029","locations":["Moroccan"],"countries":["Morocco"],"countries_codes":["MAR|Morocco"],"topics":["Prevention"],"weight":1,"_version_":1666138495813419008,"score":48.1106},{"pmid":32472459,"title":"Treatment algorithm for COVID-19: a multidisciplinary point of view.","text":["Treatment algorithm for COVID-19: a multidisciplinary point of view.","The novel coronavirus (Sars-CoV-2) pandemic has spread rapidly, from December to the end of March, to 185 countries, and there have been over 3,000,000 cases identified and over 200,000 deaths. For a proportion of hospitalized patients, death can occur within a few days, mainly for adult respiratory distress syndrome or multi-organ dysfunction syndrome. In these patients, clinical signs and symptoms, as well as laboratory abnormalities, suggest a cytokine storm syndrome in response to the viral infection. No current targeted treatment is yet available for COVID-19, an unknown disease up to 2 months ago, which challenges doctors and researchers to find new drugs or reallocate other treatments for these patients. Since the beginning of the COVID-19 outbreak, a growing body of information on diagnostic and therapeutic strategies has emerged, mainly based on preliminary experience on retrospective studies or small case series. Antivirals, antimalarials, corticosteroids, biotechnological and small molecules, convalescent plasma and anticoagulants are among the drugs proposed for the treatment or in tested for COVID-19. Given the complexity of this new condition, a multidisciplinary management seems to be the best approach. Sharing and integrating knowledge between specialists, to evaluate the correct timing and setting of every treatment, could greatly benefit our patients. We reviewed the literature, combining it with our experiences and our specialist knowledge, to propose a management algorithm, correlating the clinical features with laboratory and imaging findings to establish the right timing for each treatment.Key Points* Critically ill COVID-19 patients show signs of cytokine storm syndrome.* No current targeted therapy is available, but a lot of drugs are in tested.* A multidisciplinary approach is crucial to manage COVID-19.* Choosing the correct timing of treatment is of pivotal importance to avoid the most severe complications.","Clin Rheumatol","Galluccio, Felice","Ergonenc, Tolga","Garcia Martos, Alvaro","Allam, Abdallah El-Sayed","Perez-Herrero, Maria","Aguilar, Ricardo","Emmi, Giacomo","Spinicci, Michele","Terrancle Juan, Ignacio","Fajardo-Perez, Mario","32472459"],"abstract":["The novel coronavirus (Sars-CoV-2) pandemic has spread rapidly, from December to the end of March, to 185 countries, and there have been over 3,000,000 cases identified and over 200,000 deaths. For a proportion of hospitalized patients, death can occur within a few days, mainly for adult respiratory distress syndrome or multi-organ dysfunction syndrome. In these patients, clinical signs and symptoms, as well as laboratory abnormalities, suggest a cytokine storm syndrome in response to the viral infection. No current targeted treatment is yet available for COVID-19, an unknown disease up to 2 months ago, which challenges doctors and researchers to find new drugs or reallocate other treatments for these patients. Since the beginning of the COVID-19 outbreak, a growing body of information on diagnostic and therapeutic strategies has emerged, mainly based on preliminary experience on retrospective studies or small case series. Antivirals, antimalarials, corticosteroids, biotechnological and small molecules, convalescent plasma and anticoagulants are among the drugs proposed for the treatment or in tested for COVID-19. Given the complexity of this new condition, a multidisciplinary management seems to be the best approach. Sharing and integrating knowledge between specialists, to evaluate the correct timing and setting of every treatment, could greatly benefit our patients. We reviewed the literature, combining it with our experiences and our specialist knowledge, to propose a management algorithm, correlating the clinical features with laboratory and imaging findings to establish the right timing for each treatment.Key Points* Critically ill COVID-19 patients show signs of cytokine storm syndrome.* No current targeted therapy is available, but a lot of drugs are in tested.* A multidisciplinary approach is crucial to manage COVID-19.* Choosing the correct timing of treatment is of pivotal importance to avoid the most severe complications."],"journal":"Clin Rheumatol","authors":["Galluccio, Felice","Ergonenc, Tolga","Garcia Martos, Alvaro","Allam, Abdallah El-Sayed","Perez-Herrero, Maria","Aguilar, Ricardo","Emmi, Giacomo","Spinicci, Michele","Terrancle Juan, Ignacio","Fajardo-Perez, Mario"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32472459","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s10067-020-05179-0","keywords":["algorithm","covid-19","management","sars-cov-2"],"topics":["Treatment"],"weight":1,"_version_":1668255193320390656,"score":45.191677}]}